Key result
Patients receiving novel oral anticoagulant treatment developed thromboembolism, highlighting potential risks due to the lack of available laboratory tests for effective dose measurement.
Why the study?
Laboratory tests for follow-up and effective dose measurement of novel oral anticoagulants are not available, leading to uncertainty about their complications and effective use.
Case Report
This case report highlights the potential risk of thromboembolic events such as pulmonary embolism in patients on novel oral anticoagulants, suggesting challenges related to the lack of effective dose monitoring.
Abs tractIn this case report, we evaluated the risk of pulmonary embolism in patients using new-generation anticoagulant drugs.Laboratory tests for follow-up and effective dose measurement of new-generation oral anticoagulants, which are very popular in the medical community today, are not available.Therefore, patients can be at risk for effective doses and drug selection.Although our cases received novel oral anticoagulant treatment, it was determined that they had thromboembolism.We emphasized that we do not have enough information about the complications and effective use of these drugs, which are advantageous in terms of use and side effects.This situation may lead us to negative situations that we cannot manage in the future.
No takes yet. Share an insight, caveat, or question.
Biçen et al. (2024) conducted a case report in Pulmonary embolism. Novel oral anticoagulants was evaluated on Thromboembolism (pulmonary embolism). Patients receiving novel oral anticoagulant treatment developed thromboembolism, highlighting potential risks due to the lack of available laboratory tests for effective dose measurement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: